Communicating Health Economic Evidence: From Model Outputs to Policy Briefs

อ่านฉบับภาษาไทย (Thai version)

Abstract

A useful policy brief begins with the decision that someone must make and the options available before the deadline. Model outputs then explain the consequences of those options. This article shows how to connect absolute health gains, incremental costs and net monetary benefit with a stated decision threshold. A worked example reports value and annual budget impact separately, because their populations and time horizons can differ. We explain why a cost-effectiveness probability is conditional on model assumptions and is not the probability that a patient benefits. A complete brief also identifies who gains access, who bears costs and whose care could be displaced. Uncertainty about evidence remains distinct from judgments about fairness and priority. Recommendations should offer implementable choices, conditions and monitoring triggers, rather than disguise an unsupported verdict as a calculation. Concise references and an accessible methods appendix let readers inspect the assumptions without burying the decision. Clear communication makes trade-offs visible and revision possible.

🔍 Click to enlarge Click anywhere to close

Name the reader, decision and deadline

A policy brief is a short account of a decision problem, its options and their consequences [1]. Name the decision-making audience and when action is needed. Specify the target population, current care and practical alternatives. Explain what would happen if the decision were deferred.

Lead with options rather than a model acronym. A purchasing team needs price and implementation conditions; a coverage committee also needs access and distributional consequences. Use the same comparator and population across summaries, or explain why they differ. Keep the methods available without making them the opening argument.

Report absolute gains before the ratio

Report additional health $\Delta E$, additional cost $\Delta C$ and their common horizon. A quality-adjusted life year (QALY) combines survival and health preference weights. The incremental cost-effectiveness ratio (ICER) is $\Delta C/\Delta E$. State the sign and comparator so the ratio can be interpreted.

Incremental net monetary benefit (INMB) is $\lambda\Delta E-\Delta C$, where $\lambda$ is the stated willingness-to-pay assumption. Positive INMB favors the intervention under that value criterion. It does not establish affordability, certainty or ethical priority. Explain any dominance findings before presenting a ratio [3].

Calculate incremental value

# Writes: stdout only; coordinator captures results.
health_gain <- 0.25
incremental_cost <- 30000
willingness_to_pay <- 160000
icer <- incremental_cost / health_gain
inmb <- willingness_to_pay * health_gain - incremental_cost
cat("Lifetime incremental QALY:", formatC(health_gain, digits=3, format="f"), "\n")
cat("ICER THB per QALY:", icer, "\n")
cat("INMB THB:", inmb, "\n")

During startup - Warning messages:
1: Setting LC_COLLATE=C.UTF-8 failed
2: Setting LC_CTYPE=C.UTF-8 failed
3: Setting LC_MONETARY=C.UTF-8 failed
4: Setting LC_TIME=C.UTF-8 failed
Lifetime incremental QALY: 0.250
ICER THB per QALY: 120000
INMB THB: 10000

Calculate the independent annual cash flow

# Writes: stdout only; coordinator captures results.
eligible <- 2000
uptake <- 0.3
incremental_annual_cost <- 30000
treated <- eligible * uptake
budget <- treated * incremental_annual_cost
cat("Treated people:", treated, "\n")
cat("Annual budget impact THB:", format(budget, scientific=FALSE, trim=TRUE), "\n")

During startup - Warning messages:
1: Setting LC_COLLATE=C.UTF-8 failed
2: Setting LC_CTYPE=C.UTF-8 failed
3: Setting LC_MONETARY=C.UTF-8 failed
4: Setting LC_TIME=C.UTF-8 failed
Treated people: 600
Annual budget impact THB: 18000000

Say what the probability means

A cost-effectiveness acceptability curve (CEAC) reports how often an option has the highest net monetary benefit across joint parameter draws [4]. The probability is conditional on the evidence, model structure, comparators and decision threshold. It is not a patient response probability. It does not measure the chance that every assumption is correct.

The numerical example here has no uncertainty distribution, so no CEAC probability can be reported. A real brief should identify the parameters driving uncertainty and show credible sensitivity results. Explain structural alternatives and possible bias separately. More simulation draws cannot repair biased effectiveness evidence.

Separate uncertainty about facts from judgments about fairness. A poorly estimated treatment effect needs better evidence. Giving priority to severe disease is a value judgment that should be stated and deliberated. Do not hide either behind a single probability.

Offer actions, conditions and a date for review

Present adopt, negotiate, targeted access, access with evidence collection, research and defer as distinct options [2]. Identify who implements each option, its funding needs and which uncertainty it addresses. An unsupported evidence base warrants a conditional option, not a definitive adoption verdict.

Report annual spending by budget year and anticipated uptake [5]. Explain who gains health or financial protection, who waits and whose services may lose resources. Our example has no subgroup or evidence-strength data, so it cannot rank fairness or certainty. Name the missing data instead of inventing a favorable distribution.

Agree monitoring of uptake, outcomes, adverse events, spending and access gaps. Define review triggers before implementation, such as a price change, new comparative evidence or capacity shortfall. Keep concise references in the brief and a plain-language methods appendix with the input ledger, assumptions and reproducible calculations.

Use [[icer-dominance-ce-plane-and-thresholds]], [[decision-trees-markov-models-and-psa]] and [[budget-impact-equity-and-limits-of-qaly]] for the underlying analyses. A13 covers sourcing and A14 conditional pricing. Return to [[health-economics-series-guide]] to place the brief within the full learning route.

The series, in learning order

1. Health Economics Series Guide: Read the Evidence Before the Costs [[health-economics-series-guide]]
2. Incidence, Prevalence and the Right Denominator: The Epidemiology Beneath Cost-of-Illness and Markov Models [[incidence-prevalence-and-the-right-denominator]]
3. Design, Model and Estimand: What Each Study Design Can Actually Estimate [[study-design-estimand-and-effect-measures]]
4. Risk Ratio, Odds Ratio, Risk Difference and NNT: One 2×2 Table, Four Answers [[risk-ratio-odds-ratio-risk-difference-nnt]]
5. The Hazard Ratio Is Not a Risk Ratio: Proportional Hazards, Restricted Mean Survival Time and Model Inputs [[hazard-ratio-proportional-hazards-rmst]]
6. Chance, Bias and Confounding: Why an Association Is Not Yet a Treatment Effect [[chance-bias-and-confounding]]
7. Beyond the Evidence Pyramid: GRADE Certainty and Choosing Effectiveness Inputs for Economic Models [[evidence-pyramid-versus-grade-certainty]]
8. From Sensitivity to Cost per Case Detected: Predictive Values, Prevalence and the Economics of Screening [[diagnostic-accuracy-predictive-values-screening]]
9. Whose Cost, in Which Year? Perspective, Opportunity Cost, Inflation and Discounting [[costing-perspective-inflation-discounting]]
10. QALY, DALY and the Utilities Behind Them: What Is Actually Being Measured [[qaly-daly-and-utility-elicitation]]
11. ICER, Dominance and the Cost-Effectiveness Plane: Reading the Thai Threshold of 160,000 Baht per QALY [[icer-dominance-ce-plane-and-thresholds]]
12. Decision Trees, Markov Cohorts and Probabilistic Sensitivity Analysis: How a Model Turns Evidence into a Decision [[decision-trees-markov-models-and-psa]]
13. Cost-Effective Is Not Affordable, and Efficient Is Not Fair: Budget Impact and Equity [[budget-impact-equity-and-limits-of-qaly]]
14. Parameter Sourcing, Reference Cost Lists and Utility Catalogues When Local Data Are Sparse
15. Early Health Technology Assessment, Headroom Pricing and Benefit-Package Decisions
16. Communicating Health Economic Evidence: From Model Outputs to Policy Briefs (this article)

Related in the wiki: Health Economics Series Guide: Read the Evidence Before the Costs · ICER, Dominance and the Cost-Effectiveness Plane: Reading the Thai Threshold of 160,000 Baht per QALY · Decision Trees, Markov Cohorts and Probabilistic Sensitivity Analysis: How a Model Turns Evidence into a Decision · Cost-Effective Is Not Affordable, and Efficient Is Not Fair: Budget Impact and Equity